drug-eluting stents

By pass y actividad de la enfermedad en la arteria coronaria nativa

Long-Term Results from the BEST Study: Drug-Eluting Stents vs. Bypass Surgery in Diabetic Patients with Multiple Vessel Disease

The impact of diabetes on the development of cardiovascular disease is widely known, with a strong association with extensive and diffuse coronary artery disease. Decision-making regarding how to revascularize patients with multi-vessel disease is a complex process. In this context, coronary artery bypass grafting (CABG) has been recommended over percutaneous coronary intervention (PCI) based on<a href="https://solaci.org/en/2023/10/31/long-term-results-from-the-best-study-drug-eluting-stents-vs-bypass-surgery-in-diabetic-patients-with-multiple-vessel-disease/" title="Read more" >...</a>

Los DES de última generación presentan mejores resultados en puentes venosos que los DES antiguos y BMS

Drug-Eluting Stents vs. Balloons While Paclitaxel Is in the Eye of the Storm

Even after the US Food and Drug Administration (FDA) issued an alert on paclitaxel devices in patients with femoropopliteal artery disease, which caused the interruption of a few ongoing studies, reality indicates that the efficacy of these devices has been proven and that they are still used. The increased mortality observed in the meta-analysis that<a href="https://solaci.org/en/2019/04/09/drug-eluting-stents-vs-balloons-while-paclitaxel-is-in-the-eye-of-the-storm/" title="Read more" >...</a>

imperial-TCT 2018

TCT 2018 | IMPERIAL: First Study Comparing Drug-Eluting Stents in Patients with Femoropopliteal Disease

The IMPERIAL trial compared the safety and efficacy of a nitinol self-expanding polymer-free placlitaxel-eluting stent (Zilver PTX, Cook Medical, already approved by the US Food and Drug Administration [FDA]) and a nitinol self-expanding polymer-coating placlitaxel-eluting stent (Eluvia, Boston Scientific). This was a single-blind randomized trial in patients with symptomatic intermittent claudication (Rutherford categories 2, 3, or<a href="https://solaci.org/en/2018/10/03/tct-2018-imperial-first-study-comparing-drug-eluting-stents-in-patients-with-femoropopliteal-disease/" title="Read more" >...</a>

ivus vs angiografia nuevos stents farmacologicos

IVUS vs. Angiography in New-Generation Drug-Eluting Stents Preimplantation

Courtesy of Dr. Guillermo Migliaro. The latest 2011 American College of Cardiology (ACC) guideline states that “coronary intravascular ultrasonography (IVUS) may be considered for guidance of coronary stent implantation, particularly in cases of left main coronary artery stenting (Class IIB, Level of Evidence: B).” This has been long debated with no clear winners. This analysis provides new information<a href="https://solaci.org/en/2016/11/01/ivus-vs-angiography-drug-eluting-stents/" title="Read more" >...</a>

I-LOVE-IT2: Drug-eluting stents with a permanent polymer versus biodegradable in the same cobalt chromium platform

There is no strong evidence in the literature that the polymer type isolated (permanent or degradable) influences clinical outcomes after angioplasty and if the time of double anti-aggregation should be different with the degradable polymer. This work, with non-inferiority design, aimed to compare the sirolimus-eluting biodegradable polymer stent (Tivoli) versus the permanent polymer sirolimus-eluting stent<a href="https://solaci.org/en/2015/06/24/congress-item-8358/" title="Read more" >...</a>

PROTECT: A comparison of thrombosis incidence between the drug-eluting stents sirolimus and zotarolimus.

Summary: Randomized, open, pragmatic essay PROTECT (patient related outcomes of Endeavor versus Cypher stenting trial) compared two drug-eluting stents with different behaviors, (Cypher &reg; and Endeavor &reg;), in the reendothelialization degree and antiproliferative potency. Cypher has a permanent sirolimus-eluting polymer which generates a potent antiproliferative effect and a suboptimal healing (or reendothelialization). Furthermore, Endeavor has<a href="https://solaci.org/en/2015/06/24/congress-item-7161/" title="Read more" >...</a>

Primary angioplasty with 2nd generation drug-eluting stents

Original title:&nbsp;Stent thrombosis with second-generation drug-eluting stents compared with bare-metal stents: Network meta-analysis of primary percutaneous coronary intervention trials in ST-segment&ndash;elevation myocardial infarction.&nbsp;Reference:&nbsp;Circ Cardiovasc Interv. 2013; Epub ahead of print. To compare the safety and efficacy of 2nd generation drug-eluting stents (DES) versus bare metal stents (BMS) in the context of primary angioplasty was conducted<a href="https://solaci.org/en/2013/12/10/n-4145/" title="Read more" >...</a>

Similar results of drug-eluting stents with biodegradable polymer versus permanent

Original title:&nbsp;Biodegradable Polymer Biolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting StentA Randomized, Controlled, Noninferiority Trial.NEXT trial.&nbsp;Reference:&nbsp;Masahiro Natsuaki et al. J Am CollCardiol 2013;62:181&ndash;90. Drug-eluting stents with biodegradable polymer were designed to counteract the long-term adverse effects on the vascular wall of permanent polymer.&nbsp; This prospective, multicenter, randomized, non-inferiority design study, compared the biolimus eluting stent with<a href="https://solaci.org/en/2013/11/15/n-4075/" title="Read more" >...</a>

2nd generation drug-eluting stents intended for left main coronary artery

Original title:&nbsp;Zotarolimus- versus Everolimus-Eluting Stents for Unprotected Left Main Coronary Artery Disease. ISAR-LEFT MAIN 2 Study.&nbsp;Reference:&nbsp;Julinda Mehilli et al. J Am Coll Cardiol, article in press. Improvements in 2nd generation drug-eluting stents led to increased efficiency and safety , however there is little information on these new platforms to treat left main coronary artery .<a href="https://solaci.org/en/2013/08/29/n-3564/" title="Read more" >...</a>

Top